The three-drug combination of encorafenib, binimetinib and cetuximab significantly improved overall survival (OS) in patients with BRAF-mutated metastatic colorectal cancer (mCRC), according to results of the BEACON CRC Phase ...
Jul 6, 2019
0
2
The protein BRAF is a key player in the development of many different types of cancer, including melanoma. Scientists have known that BRAF becomes activated by growth factors and subsequently stimulates downstream proteins ...
Apr 24, 2019
0
8
Melanoma is one of the most aggressive types of skin cancer, but recent advances in targeted therapies have improved the prognosis for many patients. Unfortunately, for some patients these positive outcomes are not long lasting, ...
Apr 15, 2019
0
3
Mount Sinai researchers have discovered a previously unknown reason for drug resistance in a common subtype of melanoma, one of the deadliest forms of cancer, and in turn, have found a new therapy that could prevent or reverse ...
Aug 24, 2018
0
0
New research has shown that ovarian cancer patients with a tumour mutation in the BRAF gene respond exceptionally well to treatment with targeted drugs, known as BRAF inhibitors.
Jul 30, 2018
0
2
(HealthDay)—For patients undergoing resection of colorectal liver metastases (CRLM), the presence of the V600E BRAF mutation is associated with worse prognosis, according to a study published online May 16 in JAMA Surgery.
May 21, 2018
0
1
Cancer cells that develop resistance to drugs pay a price for this by simultaneously developing a new vulnerability. If this acquired vulnerability can be identified, it may be exploited clinically. A team of cancer researchers, ...
May 10, 2018
2
17
Patients with advanced or metastatic melanoma have been able to live longer cancer-free lives because of several new therapies approved over the last decade, such as BRAF and MEK inhibitors. However, despite the success of ...
Apr 19, 2018
0
5
The novel ERK1/2 kinase inhibitor ulixertinib displayed an acceptable safety profile and had clinical activity in patients whose tumors had mutations in the MAPK cell-signaling pathway, according to data from a phase I clinical ...
Dec 15, 2017
0
6
In a new study, Yale researchers describe the role of a protein that promotes growth of melanoma, the deadliest form of skin cancer.
Dec 6, 2017
0
0
